Search Immortality Topics:

Page 11,359«..1020..11,35811,35911,36011,361..11,37011,380..»


New therapy helps Marines suffering combat stress

Posted: September 25, 2012 at 4:11 pm

3:50 p.m. PDT, September 24, 2012

SAN DIEGO -- Symptoms of Post-Traumatic Stress Disorder are eased by a combination of guided imagery and a specific type of therapy called "Healing Touch,'' the Scripps Center for Integrative Medicine announced Monday.

Results of a study of 123 Marines who returned from deployment to Camp Pendleton between July 2008 and August 2010 were released in the September issue of the publication Military Medicine. Those selected were experiencing traumatic flashbacks, nightmares,emotional numbness, insomnia and other PTSD symptoms.

The 68 participants who went through six sessions over three weeks with Healing Touch and guided imagery fared much better than the 55 who received normal treatment, according to Scripps.

"Scores for PTSD symptoms decreased substantially, about 14 points and below the clinical cutoffs for PTSD,'' said Dr. Mimi Guarneri, a Center for Integrative Medicine founder. "This indicates that the intervention was not just statistically significant, but actually decreased symptoms below the threshold for PTSD diagnosis. It made a large difference in reducing PTSD symptoms.''

According to Scripps, Healing Touch is aimed at eliciting the participant's own healing response by restoring and balancing the human biofield -- or the energy created by the body. It helps patients to relax by reducing pain and anxiety.

Guided imagery uses visualization techniques, prompted by using a compact disc, to accomplish the same tasks, the study's authors said.

Dr. Wayne Jonas, president and chief executive officer of the Samueli Institute, an Alexandria, Va.-based organization that helped with data analysis, said returning troops are looking for alternative treatments that don't involve medications.

The study was funded by The Taylor Family Foundation.

View post:
New therapy helps Marines suffering combat stress

Recommendation and review posted by G. Smith

New study shows PTSD symptoms reduced in combat-exposed military via integrative medicine

Posted: September 25, 2012 at 4:11 pm

Public release date: 24-Sep-2012 [ | E-mail | Share ]

Contact: Keith Darce darce.keith@scrippshealth.org 858-678-7121 Scripps Health

SAN DIEGO (Sept. 24, 2012) Healing touch combined with guided imagery (HT+GI) provides significant clinical reductions in post-traumatic stress disorder (PTSD) symptoms for combat-exposed active duty military, according to a study released in the September issue of Military Medicine.

The report finds that patients receiving these complementary medicine interventions showed significant improvement in quality of life, as well as reduced depression and cynicism, compared to soldiers receiving treatment as usual alone.

The study, led by the Scripps Center for Integrative Medicine in San Diego, Calif., conducted a randomized controlled trial of returning active-duty Marines at Camp Pendleton, Calif. from July 2008 to August 2010. Participants were separated at random into two groups, one that received treatment as usual (TAU) for PTSD and another that received TAU as well as healing touch (HT), a practitioner-based treatment aimed at eliciting the participant's own healing response, with guided imagery (GI), a self-care therapy aimed at eliciting relaxation as well as enhancing trust and self-esteem.

Significant Improvements Reported

After six sessions within a three-week period with a Scripps practitioner, the HT+GI group reported a significant improvement in PTSD symptoms as a result of these combined complementary therapies.

The principal investigators and designers of the study are Dr. Mimi Guarneri and Rauni King, founders of the Scripps Center for Integrative Medicine. The Samueli Institute of Alexandria,Va., conducted blind data analysis and authored the manuscript.

"Scores for PTSD symptoms decreased substantially, about 14 points and below the clinical cutoffs for PTSD," said Dr. Guarneri. "This indicates that the intervention was not just statistically significant, but actually decreased symptoms below the threshold for PTSD diagnosis. It made a large difference in reducing PTSD symptoms."

Study Criteria

Read more from the original source:
New study shows PTSD symptoms reduced in combat-exposed military via integrative medicine

Recommendation and review posted by G. Smith

What is this thing called love? Mere chemical trickery

Posted: September 25, 2012 at 4:10 pm

Kayt Sukel, contributor

In The Chemistry Between Us, neuroscientist Larry Young and journalist Brian Alexander examine the neurobiological roots of love

THERE is a reason most of us sigh into our drinks when Cole Porter croons, "What is this thing called love?" We understand his befuddlement all too well. (And let's face it: if a man about town like Porter couldn't figure out this whole love thing, what hope is there for the rest of us mere mortals?)

That's why it is encouraging to know that in the past two decades social neuroscientists have been diligently working to unravel the mysteries of love - including the phenomena of attraction, monogamy and the parent-child bond - using techniques such as brain imaging, genome-wide association studies and transgenic animal models. In The Chemistry Between Us, Larry Young, the director of Emory University's Center for Translational Social Neuroscience, and journalist Brian Alexander offer a novel take on many of those findings.

A few recent books, including my own, Dirty Minds, have chronicled love and sex-related efforts in neuroscience. One of the criticisms of many of these tomes is that they fail to take on the functional "why" questions - why monogamy exists at all, for example, or why some people are more prone to infidelity. In The Chemistry Between Us, Young and Alexander do not shy away from proposing some strong hypotheses about the ways our neurobiology shapes our behaviour when it comes to the "L" word.

Drawing on real stories as well as research, the authors take the reader on a fascinating journey through strip clubs, Romanian orphanages and labs where rodents are regularly stimulated with lubed paintbrushes. These myriad adventures provide a great context for the science - and cleverly illustrate all the ways in which love and sex can make changes to our brain chemistry.

While those who closely follow the latest neurobiological research concerning love and sex might not find many new studies in this mix, they will find a rather unique interpretation of how they all fit together.

Young, who is arguably one of most prolific researchers in the social neuroscience field, plants his flag firmly: he argues that love is truly an addiction and one to which none of us are immune. He takes a reductionist approach, focusing on molecules like dopamine, oxytocin and vasopressin, and examining how these chemicals exploit ancient neurobiological circuits.

Some may feel uncomfortable when Young and Alexander claim that sex tricks women into "babysitting" the men they love - nurturing them as they would their own infants, thanks to the goodly amounts of oxytocin released during the sex act by men hitting the cervix with their large penises and playing with their breasts. Sceptics probably won't feel much better when Young and Alexander postulate that vasopressin helps men see their female partners as simply extensions of their territory.

Still, the authors don't back down. "Many would like to believe that such notions are outdated stereotypes," they write. "They're not. We can fake it, but nature gets the last word." Not overly concerned with political correctness, Young and Alexander even go so far as to extend these hypotheses to touch on modern issues like marriage equality and single motherhood.

See original here:
What is this thing called love? Mere chemical trickery

Recommendation and review posted by G. Smith

UCSB Professors Receive National Chemistry Awards

Posted: September 25, 2012 at 4:10 pm

Two UC Santa Barbara professors have been named recipients of the American Chemical Societys 2013 national awards for professionaladvancement. Peter C. Ford, professor in the Department of Chemistry and Biochemistry, and Craig J. Hawker, also a professor in the Department of chemistry and Biochemistry,professor of materials, and director of the Materials Research Laboratory, have been named among the 64 award winners from across the country

In only one other year, 1996, did UCSB have more than one winner of theAmerican Chemical Society (ACS) awards. The awards will be presented at the nationalACS meeting in New Orleans in April.Ford is the recipient of the ACS Award for Distinguished Service in the Advancement of Inorganic Chemistry. This award recognizes individuals who haveadvanced inorganic chemistry by significant service, in addition to performingoutstanding research. It is sponsored by StremChemicals.

I am of course very pleased and honored to have received this award from my colleagues in the American Chemical Society, saidFord.

Since this is largely in recognition of the body of work generated by my graduate and postdoctoral students and collaborators over my tenure at UCSB, I consider it an award to my research group collectively as well as another testament to the high regard in which this campus is nowheld. I am proud to be aGaucho.

Hawker has been named recipient of the ACS Award in Polymer Chemistry. Thecitation states that Hawker was nominated for transforming the field of polymer chemistry through the clever adaptation of synthetic organic chemistry concepts and theadvancement of macromolecular engineering. ExxonMobil Chemical Company sponsored thisaward.

I am thrilled with the award and the recognition that it brings to my students, collaborators, and co-workers, as well as to the unique research environment at UCSB, said Hawker. The sustained success of cross-disciplinary research has been a key driver in reinforcing UCSBs international standing in the materials chemistry arena. I am grateful for the enormous benefits that this proud tradition has bought to myresearch.

Ford joined the faculty at UCSB in 1967 after earning his Ph.D. at Yale and completing a National Science Foundation postdoctoral fellowship with Nobel laureateHenry Taube at Stanford University. He is a Fellow of the American Association for theAdvancement of Science and was a Senior Fulbright Fellow. His awards include a Dreyfus Foundation Teacher-Scholar Award in 1972; the Alexander von Humboldt Foundation Senior U.S. Scientist Award in 1992; the Richard C. Tolman Medal of theACS in 1993; and the Inter-American Photochemical Society Award in Photochemistry in2008.

Hawker received his Ph.D. from the University of Cambridge, and then completeda postdoctoral fellowship with Jean M. J. Frchet at Cornell. In 2004, he moved from theIBM Almaden Research Center to join the faculty at UCSB. Some of his recent awardsinclude the 2012 Centenary prize from the Royal Society of Chemistry; the 2011 Arthur C. Cope Scholar from the American Chemical Society; and the 2008 DSM PerformanceMaterials Award from the International Union of Pure and Applied Chemistry. In 2010,he was named a Fellow of the RoyalSociety.

See more here:
UCSB Professors Receive National Chemistry Awards

Recommendation and review posted by G. Smith

BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

Posted: September 25, 2012 at 4:10 pm

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces Therapeutic Workshops on Cancer stem cell therapy, kinase drugs, and ultra rare diseases planned for the upcoming BIO Investor Forum. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

This years Therapeutic Workshops will address some of the most exciting therapeutic advances for the biotech industry. We have worked very closely with this years esteemed Advisory Committee to identify topics that will engage investors and industry alike, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

Therapeutic Workshops will feature senior-level industry executives, scientific officers and leading clinical experts that represent innovative investment opportunities in the biotech industry.

Therapeutic Workshops include:

The BIO Investor Forum features public and venture-stage company presentations, expert-led, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Advance media registration is available here. Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Follow this link:
BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

Recommendation and review posted by G. Smith

Ovizio And Applikon Biotechnology Sign Long Term Marketing And Distribution Agreement

Posted: September 25, 2012 at 4:10 pm

Ovizio Imaging Systems and Applikon Biotechnology jointly announce today the signing of a long term worldwide marketing and distribution agreement for an innovative device using a proprietary imaging technology in microscopy.

Applikon will market worldwide an innovative and integrated solution, developed by Ovizio, that combines 4D microscopic imaging with the Applikon bioreactor systems. This new device will offer automated on-line information on cell density, cell viability and morphologic state of the cells.

Applikon and Ovizio have a common vision of the potential of optical image analysis in bioprocessing said Erik Kakes, commercial director of Applikon Biotechnology. "We feel that using optical 4D image analysis for determination of biomass concentration and viability is only the first step in applying this revolutionary technology to the bioprocess industry", he added.

We are absolutely delighted to partner with a company having such an in-depth knowledge of the market and strong reputation within the Bioprocess industry, said Philip Mathuis, CEO of Ovizio. We believe that quantitative imaging as a new Process Analytical Technology (PAT) applied to on-line bioreactor monitoring will allow Biopharma customers to improve process knowledge, quality and productivity in their R&D, Pilot and Production environments.

The new device will be jointly presented at the next Het Instrument Amsterdam, exhibition on 26 September 2012.

About Ovizio Imaging Systems NV/SA Ovizio is a spin-off company of the Universit Libre de Bruxelles (ULB). The company designs, develops and markets 4-D quantitative imaging systems and sensors based on patented Digital Holographic Microscopy with a primary focus on the Life Science Research, Biotechnology and Bioprocessing industry..

Ovizios platform technology unifies real-time quantitative imaging with speed and a label-free, non-invasive approach. Our advanced devices generate high quality holographic images ideal for studying dynamic phenomena, breaking the barriers between the traditional speed of flow cytometry and the resolution of classical microscopy.

Ovizio is a privately held company situated in Brussels, Belgium. For more information, visit http://www.ovizio.com.

SOURCE: Applikon Biotechnology

See the original post:
Ovizio And Applikon Biotechnology Sign Long Term Marketing And Distribution Agreement

Recommendation and review posted by G. Smith


Page 11,359«..1020..11,35811,35911,36011,361..11,37011,380..»